JPMorgan Chase & Co. Increases Stake in Phreesia, Inc. (NYSE:PHR)

JPMorgan Chase & Co. lifted its position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 144.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,716 shares of the company's stock after acquiring an additional 86,040 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.25% of Phreesia worth $3,666,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PHR. R Squared Ltd bought a new position in Phreesia in the fourth quarter valued at about $30,000. BankPlus Trust Department bought a new position in Phreesia in the 4th quarter valued at approximately $34,000. Venturi Wealth Management LLC acquired a new stake in Phreesia during the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC grew its holdings in Phreesia by 154.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company's stock worth $89,000 after acquiring an additional 2,090 shares during the last quarter. Finally, LPL Financial LLC acquired a new position in Phreesia in the 4th quarter valued at approximately $216,000. Institutional investors and hedge funds own 92.10% of the company's stock.

Wall Street Analyst Weigh In

PHR has been the topic of several analyst reports. KeyCorp reduced their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. DA Davidson reduced their price target on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Royal Bank of Canada raised Phreesia from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Finally, Piper Sandler reissued an "overweight" rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $31.33.

Phreesia Stock Up 1.0 %

Shares of PHR stock traded up $0.24 on Thursday, reaching $24.42. 138,199 shares of the company were exchanged, compared to its average volume of 433,375. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -16.60 and a beta of 0.82. The company has a 50-day moving average of $25.72 and a 200-day moving average of $24.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Insider Buying and Selling at Phreesia

In related news, COO Evan Roberts sold 3,519 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total value of $105,781.14. Following the transaction, the chief operating officer now owns 741,197 shares of the company's stock, valued at approximately $22,280,381.82. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,213 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $28,881.53. Following the completion of the transaction, the general counsel now owns 137,921 shares of the company's stock, valued at $3,283,899.01. This trade represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 147,057 shares of company stock valued at $4,070,658. Company insiders own 5.80% of the company's stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.